Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reiterated by BTIG Research in a research note issued to investors on Sunday. They presently have a $32.00 price target on the stock. BTIG Research’s price target points to a potential upside of 31.80% from the stock’s current price.
VYGR has been the subject of several other research reports. Zacks Investment Research raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. Wedbush boosted their price objective on Voyager Therapeutics from $22.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, February 21st. Morgan Stanley boosted their price objective on Voyager Therapeutics from $36.00 to $39.00 and gave the company an “overweight” rating in a report on Wednesday, February 21st. Canaccord Genuity reissued a “buy” rating and issued a $26.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, January 23rd. Finally, BidaskClub raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. Voyager Therapeutics presently has a consensus rating of “Buy” and an average target price of $29.20.
Voyager Therapeutics (NASDAQ VYGR) opened at $24.28 on Friday. The stock has a market capitalization of $724.67 and a PE ratio of -8.55. Voyager Therapeutics has a fifty-two week low of $8.10 and a fifty-two week high of $31.91.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in Voyager Therapeutics by 73.9% in the 4th quarter. BlackRock Inc. now owns 1,210,763 shares of the company’s stock worth $20,099,000 after purchasing an additional 514,345 shares during the period. Farallon Capital Management LLC raised its holdings in Voyager Therapeutics by 290.5% in the 4th quarter. Farallon Capital Management LLC now owns 654,812 shares of the company’s stock worth $10,870,000 after purchasing an additional 487,147 shares during the period. Wells Fargo & Company MN raised its holdings in Voyager Therapeutics by 19.2% in the 4th quarter. Wells Fargo & Company MN now owns 449,525 shares of the company’s stock worth $7,462,000 after purchasing an additional 72,335 shares during the period. Vanguard Group Inc. raised its holdings in Voyager Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after purchasing an additional 13,194 shares during the period. Finally, AXA acquired a new position in Voyager Therapeutics in the 4th quarter worth about $5,591,000. 80.03% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Voyager Therapeutics (VYGR) Given Buy Rating at BTIG Research” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.themarketsdaily.com/2018/03/13/voyager-therapeutics-vygr-given-buy-rating-at-btig-research.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.